Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in China Ignis obtains rights to develop and commercialize NeuroSigma’s FDA-approved Monarch eTNS System in China Initial launch of Generation 1.0...
NeuroSigma Announces Promotion of Dr. Colin Kealey to PresidentLOS ANGELES, Jan. 11, 2022 (GLOBE NEWSWIRE) - NeuroSigma, Inc., a bioelectronic medical device company, today announced the promotion...
NeuroSigma Announces a $5 Million Equity Investment by KT CorporationTransaction follows the June 2021 announcement of a strategic digital health partnership between NeuroSigma and KT Significant investment...